Jamie Phares, Managing Director, Janssen, the Pharmaceutical Companies of Johnson & Johnson in the GCC, comments on the evolving approach to…

PharmaBoardroom’s ten most-read executive interviews of 2021 reflect the wide scope – in terms of both geography and value chain – that our work…

Becoming the clinical trials country leader in the region has been set as a primary goal for Turkey’s pharma industry to achieve global…

Cyril Titeux, senior VP mid-sized markets EMEA & strategic leader at Janssen, argues that the current focus of many health systems on efficiency,…

Data has been collected within Danish healthcare for more than 40 years, extending beyond the national patient registry to include a broad range of…

Long established as a premier early launch country for innovative medicines within Europe, the Danish market access system has become more complicated…

Julie Enevold Brooker discusses what she sees as Janssen’s responsibility to help improve the Danish healthcare system beyond just bringing…

Drawing on over a dozen interviews with C-level pharmaceutical industry executives in Turkey, PharmaBoardroom has compiled a strategic overview of…

PharmaBoardroom has spread its wings far and wide in 2021 (albeit digitally!), from well covered markets such as Singapore and Switzerland to new…

With Africa struggling to vaccinate its populations against COVID-19, the World Bank – along with government institutions from the USA, Germany, and…

After an international career spanning 25 years, Demet Russ returned to her native Turkey to lead the Janssen affiliate during a tumultuous time and…

Janssen’s Managing Director for Turkey, Demet Russ, discusses her return to the country after 25 years abroad, having worked for Johnson &…